The “open data” movement runs aground on FOURIER
Dr. Anish Koka
JANUARY 18, 2023
Discovering discrepancies in a major published trial from the pharma-academic complex would be a boost to those seeking to force trial data to be public, and that is exactly what a group of investigators attempted to do with a major cholesterol lowering trial published in 2017. Cholesterol lowering is big business. billion dollars.
52 
Let's personalize your content